Voyager Therapeutics Inc (VYGR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Voyager Therapeutics Inc stock $2.35, price $1.87, upside +25.7%, quality 28 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $1.72 – $13.99 · fair‑value band $1.55 – $2.94 · the $1.87 price screens below the $2.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Voyager Therapeutics in your weekly email
Every Wednesday you see whether Voyager Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Show moreShow less
The company also provides research program for the treatment of Huntington's disease.
In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology.
The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Stock analysis
Voyager Therapeutics Inc (VYGR) currently trades at $1.87, while our model-based Fair Value estimate is $2.35, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.55 (bear) to $2.94 (bull), the price of $1.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Voyager Therapeutics Inc reported revenue of $40.4M in FY2025 versus $37.4M in FY2021, a compound +1.9%/yr. Reported net income was −$120M in FY2025.
Key figures
Market cap $113M Micro · P/S ratio 4.62 · EPS (TTM) $−1.74 · Return on equity −58.9% · Return on assets (EBIT) −21.7% (5-year average) · Operating margin −658% · Revenue (TTM) $25.1M · Revenue growth (YoY) −70.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 26%, VYGR screens cheaper than that median.
Fair Value models
Bear$1.55Fair Value $2.35Bull$2.94
Price $1.87 · Upside +25.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
SaleAlfred SandrockPresident and CEO, Director4× since Feb 10, 2026: 49,632 shares, avg. $3.72$184,446Apr 2, 2026
SaleTodd Alfred CarterChief Scientific Officer3× since Feb 10, 2026: 11,000 shares, avg. $3.69$40,621Feb 24, 2026
SaleNathan D. JorgensenChief Financial Officer4,668 shares at $3.77$17,598Feb 24, 202610b5-1 plan
SaleRobin SwartzCOO & CBO3× since Feb 10, 2026: 14,909 shares, avg. $3.71$55,291Feb 24, 2026
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−49.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.1%
Start year 2020 (pandemic). Over 10 years: +8.8% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.0% (2020) → −326.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Voyager Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside+25.7% · Top 25%
Profitability
Return on assets−47.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−70.0% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Voyager Therapeutics Inc (VYGR) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.35 versus a price of $1.87, about +26% upside (undervalued).
What is the fair value of VYGR?
Our model-based fair value for Voyager Therapeutics Inc is $2.35 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.87.
What is the quality score of VYGR?
Voyager Therapeutics Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Voyager Therapeutics Inc (VYGR)?
Our model-based price target is the fair value of $2.35 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.55, optimistic scenario $2.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Voyager Therapeutics Inc stock forecast for 2026?
Our models put fair value at $2.35, about +26% upside versus a price of $1.87 (undervalued). Cautious scenario $1.55, optimistic scenario $2.94. The calculation is refreshed regularly with new filings.
What is the revenue of Voyager Therapeutics Inc (VYGR)?
Voyager Therapeutics Inc reported trailing-twelve-month revenue of about $25.1M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Voyager Therapeutics Inc (VYGR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Voyager Therapeutics Inc it is $2.35 per share (as of Nov 8, 2026), against a price of $1.87. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Voyager Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, VYGR trades below its calculated fair value: price $1.87, fair value $2.35, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VYGR?
No. The price is what the market pays today ($1.87); the fair value is what the company's own numbers justify ($2.35). For Voyager Therapeutics Inc the two are $0.4800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Voyager Therapeutics Inc worth?
The market values Voyager Therapeutics Inc at about $113M (market capitalisation, as of Nov 8, 2026). Per share that is $1.87; our models calculate a fair value of $2.35 per share.
What do the bullish and bearish scenarios say about VYGR?
Our models span a range for Voyager Therapeutics Inc: cautious scenario $1.55, base $2.35, optimistic $2.94 per share (as of Nov 8, 2026, price $1.87). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Voyager Therapeutics Inc (VYGR)?
Balance-sheet figures for Voyager Therapeutics Inc (as of Nov 8, 2026): return on equity −58.9%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is VYGR from its 52-week high?
Voyager Therapeutics Inc trades at $1.87, about 63% below its 52-week high of $5.00 and 9% above the low of $1.72 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.35 is for.
Which stocks are comparable to Voyager Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Voyager Therapeutics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $1.87, calculated fair value $2.35 (+26%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VYGR calculated?
We run Voyager Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $2.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Voyager Therapeutics Inc currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Voyager Therapeutics Inc (VYGR)?
The closing price on Nov 6, 2026 was $1.87. Our model-based fair value is $2.35, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Voyager Therapeutics Inc right now?
A fairly wide model range ($1.55 to $2.94) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Voyager Therapeutics Inc
How large is the market capitalisation of Voyager Therapeutics Inc (VYGR)?
The market capitalisation of Voyager Therapeutics Inc is $113M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Voyager Therapeutics Inc (VYGR)?
The price-to-sales ratio of Voyager Therapeutics Inc is 4.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Voyager Therapeutics Inc (VYGR)?
Earnings per share at Voyager Therapeutics Inc are $−1.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Voyager Therapeutics Inc (VYGR)?
The return on equity (ROE) of Voyager Therapeutics Inc is −58.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Voyager Therapeutics Inc (VYGR)?
On an EBIT basis the return on assets of Voyager Therapeutics Inc is −21.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Voyager Therapeutics Inc (VYGR)?
The operating margin of Voyager Therapeutics Inc is −658% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Voyager Therapeutics Inc (VYGR)?
Revenue at Voyager Therapeutics Inc is growing −70.0% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Voyager Therapeutics Inc (VYGR) generate?
The free cash flow of Voyager Therapeutics Inc is −$135M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Voyager Therapeutics Inc (VYGR) hold?
Voyager Therapeutics Inc holds more cash than debt, $28.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Voyager Therapeutics Inc in the live analysis
One click puts Voyager Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
